Atara Biotherapeutics Inc (ATRA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Atara Biotherapeutics Inc   (NASDAQ: ATRA)


Atara Biotherapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Atara Biotherapeutics Inc's ROI in the second quarter of 2026?
Atara Biotherapeutics Inc recorded a cumulative net loss of $-17 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -145.26%.

Within the Healthcare sector 680 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2851 to 3896.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM - - - -85.73 % -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 14 14 5 12 22
Return On Investment (TTM) -145.26 % -69.98 % 242.55 % 404.88 % -1023.85 %
ATRA's Overall Ranking # 3896 # 2851 # 23 # 38 # 0
Seq. Investment Change TTM -15.08 % 0.38 % 133.18 % - -
Seq. Net Income Change TTM - - 39.69 % 303.81 % -
Net Income (TTM) in Millions -17 -9 33 23 6

ATRA Company Profile >> Back to ATRA Roi Comparisons >> See Annual ATRA Return On Investment



Return On Investment ATRA's Ranking
Within: No.
Industry # 116
Sector # 681
Overall # 3896

Return On Investment Statistics
High Average Low
404.88 %
-66.91 %
-328.66 %
(Sep 30 2025)   (Sep 30 2024)



  News about Atara Biotherapeutics Inc Return on Investment ROI

Atara Biotherapeutics Shaping the Future of T-Cell Immunotherapy at Stifel 2024,

November 13, 2024

Pioneering Innovation in T-Cell Immunotherapy: Atara Biotherapeutics Participates in Stifel 2024 Healthcare Conference In the ever-evolving landscape of biotechnology and pharmaceuticals, the emergence of cutting-edge therapies has brought renewed hope for cancer and autoimmune disease patients. Atara Biotherapeutics, Inc. a trailblazer in T-cell immunotherapy, continues to make significant strides in this arena. As the company prepares to participate in the Stifel 2024 Healthcare Conference, its efforts and innovations warrant a closer examination. The Significance of the Stifel 2024 Healthcare Conference Scheduled for November 18, 2024, at 6:10 a.m. PST / 9:10 a.m. EST, the Stifel 2024 Healthcare Conference is poised to attract attention from investors, industry experts, and stakeholders alike. This pivotal event serves as a platform for presenting and discussing the latest advancements in healthcare, biotechnology, and therapeutics. Cokey Nguyen, Ph.D. President and Chief Executive Officer of Atara Biotherapeutics, will be engaging in a fireside chat an intimate discussion format that typically allows for deeper exploration of a company s vision, strategies, and upcoming projects.





Financial Statements
Atara Biotherapeutics Inc's II. Quarter Investments $ 14 Millions ATRA's Balance sheet
Atara Biotherapeutics Inc's II. Quarter Income $ -5 Millions Quarterly ATRA's Income Statement
ATRA's Income by Division See ATRA's Income by Division


ATRA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 5 -25 23 298 362
Y / Y Investment Growth - - -92.18 % -17.89 % -22.37 %
Net Income in Millions 33 -85 -276 -228 -340
Y / Y Net Income Growth - - - - -
Annual Return On Investment 615.25 % - -1186.21 % -76.74 % -93.87 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 615.25 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ATRA's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ATRA's Competitors
Subscribers only: Roi for Atara Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for ATRA's Customers

Other Ratios
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Statistics
ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:12:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.